In collaboration with Microsoft and NVIDIA, SOPHiA GENETICS is developing a comprehensive whole genome analytical solution BOSTON and ROLLE, Switzerland, May 29, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that it is collaborating with Microsoft and NVIDIA to leverage their expertise in technology and genomics to bring a streamlined and scalable whole genome sequencing (WGS) analytical solution ...

Company Overview - SOPHiA GENETICS is a cloud-native healthcare technology company focused on data-driven medicine and is a leader in the field [5] - The company has developed the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data to provide actionable insights for hospitals, laboratories, and biopharma institutions globally [5] Industry Context - Cancer is the second most common cause of death in Brazil, with an estimated 704,000 new cancer cases expected between 2023 and 2025 [2] - Blood cancers rank as the fifth most common type of cancer worldwide [2] - Instituto Mário Penna, a major oncology service provider in Brazil, has implemented the SOPHiA DDM™ Platform to enhance its testing capabilities and improve data-driven treatment plans for blood-related cancers [2][3] Technological Advancements - The SOPHiA DDM™ Platform utilizes next-generation sequencing (NGS) to identify key variants from various sample types, facilitating rapid and accurate detection of disease-associated variants [3] - The platform is designed to compute a wide array of genomic variants and continuously improves its machine learning algorithms for better detection of rare and challenging cases [4] - Results from the SOPHiA DDM™ Platform are nearly 100 percent reproducible, ensuring consistent and reliable sequencing data [4]

"Precision medicine makes novel therapies for cancer treatment possible," said Kevin Puylaert, Managing Director, EMEA, SOPHiA GENETICS. "The implementation of the SOPHiA DDM™ Platform will help Klinikum Klagenfurt am Wörthersee produce reliable insights from its testing while saving time and valuable resources." The SOPHiA DDM™ Platform will help broaden the hospital's cancer testing and diagnostic capabilities BOSTON and ROLLE, Switzerland, May 16, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cl ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2024 was $15.8 million, representing a 13% increase from $14 million in Q1 2023, with analysis volume approximately 84,000, up 9% year-over-year [8][58] - Adjusted operating loss improved 13% year-over-year to $14.1 million compared to $16.2 million in Q1 2023 [18][79] - Gross profit for Q1 2024 was $10.4 million, a 7% increase from $9.7 million in Q1 2023, with a gross margin of 65.9% [75] Business Line Data and Key Metrics Changes - Clinical bookings grew over 30% year-over-year, with 27 new logos signed in Q1, up from 18 in the prior year [13][63] - Oncology applications outperformed rare and inherited disorders, driven by strength in solid tumor testing [66][140] - The pipeline for the clinical business grew over 50% year-over-year, while the biopharma pipeline more than doubled [71] Market Data and Key Metrics Changes - In the U.S., analysis volume grew 34% year-over-year, and revenue increased by 27% [25] - EMEA and Latin America experienced the softest growth during Q1, partially offset by significant strength in North America and Asia-Pacific, which grew at 44% and 39%, respectively [59][60] - Major wins in Asia-Pacific included partnerships in India and South Korea, expanding the company's footprint in these regions [26][27] Company Strategy and Development Direction - The company aims to capitalize on growing demand in biopharma and has developed an action plan to recover revenue in the latter half of the year [16][72] - SOPHiA GENETICS is focused on expanding access to data-driven medicines using AI, with a goal of achieving profitability in the next two-plus years [20][94] - The company has entered into a $50 million debt financing agreement to provide additional capital flexibility for growth strategies, including potential acquisitions [57][89] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in a strong back half of 2024, citing improved consumption levels and strong bookings [17][83] - The company reaffirmed its full-year revenue guidance for 2024 of $78 million to $81 million, indicating a growth of 25% to 30% year-on-year [84] - Management noted that the recent proposed LDT regulations by the FDA could ultimately benefit the company by increasing demand for testing [105][111] Other Important Information - The company reported a cash burn of $19.5 million for Q1 2024, up from $16.8 million in the prior year, attributed to unfavorable FX translation [81] - Cash and cash equivalents were approximately $103.7 million as of March 31, 2024 [82] Q&A Session Summary Question: Can you talk about the revenue rate this year and your confidence in hitting full-year guidance? - Management highlighted strong bookings and utilization trends in March and April, expecting these to fuel growth in the coming quarters [98][100] Question: Do you anticipate any impact on testing volumes due to the proposed LDT regulations by the FDA? - Management welcomed the regulations, believing they will create trust and increase demand among large academic centers and reference labs [105][107] Question: What proportion of new logos are incorporating emerging sequencing platforms? - Management noted that while Illumina remains dominant, there is increasing adoption of other sequencing technologies, particularly in regions outside the U.S. [116][118] Question: Does the new debt financing increase M&A optionality? - Management indicated a willingness to consider acquisitions that align with their growth strategy while remaining financially disciplined [119][125]

:°: SOPHiA ·°·: GENETICS™ No offer to sell or buy Market and industry data © SOPHiA GENETICS 2024 3 4 © SOPHiA GENETICS 2024 For decades, health data has been produced in silos © SOPHiA GENETICS 2024 SOPHiA DDM™ is a decentralized analytics platform which computes © SOPHiA GENETICS 2024 $25B $15B Generating insights from multimodal data to help Clinicians with screening, early detection, diagnosis, therapy selection, and monitoring The decentralized, cloud-based analytics platform at the center of it all No ...

SOPHiA GENETICS SA (SOPH) closed the last trading session at $5.05, gaining 3.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $8.33 indicates a 65% upside potential.The average comprises three short-term price targets ranging from a low of $7 to a high of $10, with a standard deviation of $1.53. While the lowest estimate indicates an increase of 38.6% from the current price leve ...

dated as of May 2, 2024 among SOPHiA GENETICS SA as Borrower, The Guarantors From Time To Time Party Hereto, as Guarantors, The Lenders From Time To Time Party Hereto, as Lenders, Execution Version Credit Agreement and Guaranty and Perceptive Credit Holdings IV, LP, as the Administrative Agent and as a Lender 4894-2985-1820 7040231 #98195096v26 Table of Contents Section Heading Page Schedules: | Schedule | 1 | — | Commitments and Warrant Shares | | --- | --- | --- | --- | | Schedule | 2 | — | Notice Address ...

BOSTON and ROLLE, Switzerland, April 30, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, today announced that Chief Financial Officer and Chief Operating Officer, Ross Muken, will present at the 2024 RBC Capital Markets Global Healthcare Conference in New York City on Tuesday, May 14, 2024, at 3:35 p.m. EDT. The presentation will be webcast live on the SOPHiA GENETICS Investor Relations website. Additionally, a replay will be available on the w ...

BOSTON and ROLLE, Switzerland, April 23, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the first quarter of fiscal year 2024 before U.S. markets open on Tuesday, May 7, 2024. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET. The call will be webcast live on th ...

BOSTON and ROLLE, Switzerland, April 23, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the first quarter of fiscal year 2024 before U.S. markets open on Tuesday, May 7, 2024. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET. The call will be webcast live on th ...